

# Internal Medicine Grand Rounds

Texas Health Presbyterian Hospital Dallas, Fogelson Bldg., Haggard Hall, 8200 Walnut Hill Lane, Dallas, TX 75231  
Noon – 1 p.m.

## HEMATOLOGY AND ONCOLOGY

November 1, 2017

### “Sarcoma: Diagnosis and Management”

**Brian A. Van Tine, M.D., Ph.D.**

*Medical Oncologist, Siteman Cancer Center – Saint Louis, Missouri*

Objectives:

- Review the correct staging, workup, and diagnosis for patients with sarcoma.
  - Identify the role of neo/adjuvant therapy in the treatment of sarcoma.
- Review the indications for the 4 new FDA approved drugs in the treatment of sarcoma.

November 8, 2017

### “2017 Update on Myeloma”

**Larry Anderson, M.D., Ph.D.**

*Associate Professor*

*Director, Myeloma, Waldenstrom's, and Amyloidosis Program; Member, Hematologic Malignancies and BMT Program  
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center – Dallas, Texas*

Objectives:

- Describe the updated criteria for differentiating MGUS and asymptomatic/smoldering myeloma from active or symptomatic myeloma requiring therapy.
- Recognize the shifting treatment paradigms of multiple myeloma including emerging regimens used in primary therapy, consolidation therapy, maintenance therapy, and relapsed/ refractory disease.
  - Discuss emerging new classes of therapeutics used primarily in the relapsed/ refractory Myeloma setting.

November 15, 2017

### “Immunotherapy in Esophageal and Gastric Cancers: Current Evidence and Future Approaches”

**(The Scott Daniel, M.D. Lectureship)**

**Joseph Chao M.D.**

*Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Gastrointestinal Cancer Program  
City of Hope National Medical Center Outpatient Clinic – Duarte, California*

Objectives:

- Discuss current evidence supporting the use of immunotherapy agents in gastroesophageal cancers.
  - Recognize and manage toxicities that may manifest from immunotherapy agents.
- Review ongoing trials expanding upon the use of immunotherapy in gastroesophageal cancers.

November 22, 2017

**CANCELLED (Thanksgiving Holiday)**

November 29, 2017

### “Updates in Hypercoagulable States/Anticoagulation”

**Srikanth Nagalla, MBBS, MS**

*Associate Professor of Internal Medicine; Director, Hematology/Oncology Fellowship  
Division of Hematology/Oncology, UT Southwestern Medical Center – Dallas, Texas*

Objectives:

- Review the appropriate use of hypercoagulability testing.
- Discuss the treatment of provoked and unprovoked VTE.

**Target Audience:** Internal medicine physicians, residents, physician assistants, nurse practitioners, nurses, allied health care professionals

**Program Director:** Kristi McIntyre, M.D. – *medical oncologist, Texas Health Presbyterian Hospital Dallas – Dallas, Texas*

**Format:** Didactic lecture with question and answer session

**Accreditation:** Texas Health Research & Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Texas Health Research & Education Institute designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Additional Information:** For more information, please call 214-345-2322 or visit our website [TexasHealth.org/CME](http://TexasHealth.org/CME).

*Doctors on the medical staff practice independently and are not employees or agents of the hospital except resident doctors in the hospital's graduate medical education program.*